1. Home
  2. CADL vs BHFAO Comparison

CADL vs BHFAO Comparison

Compare CADL & BHFAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$9.83

Market Cap

754.7M

Sector

Health Care

ML Signal

HOLD

Logo Brighthouse Financial Inc. Depositary Shares 6.75% Non-Cumulative Preferred Stock Series B

BHFAO

Brighthouse Financial Inc. Depositary Shares 6.75% Non-Cumulative Preferred Stock Series B

HOLD

Current Price

$15.09

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
BHFAO
Founded
1999
N/A
Country
United States
United States
Employees
N/A
1400
Industry
Biotechnology: Pharmaceutical Preparations
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
754.7M
N/A
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CADL
BHFAO
Price
$9.83
$15.09
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
2.1M
36.0K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
58.62
N/A
EPS
N/A
N/A
Revenue
$125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$14.19
52 Week High
$11.36
$19.99

Technical Indicators

Market Signals
Indicator
CADL
BHFAO
Relative Strength Index (RSI) 63.22 38.33
Support Level $4.89 N/A
Resistance Level N/A $15.50
Average True Range (ATR) 0.64 0.20
MACD 0.09 0.02
Stochastic Oscillator 55.40 39.27

Price Performance

Historical Comparison
CADL
BHFAO

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About BHFAO Brighthouse Financial Inc. Depositary Shares 6.75% Non-Cumulative Preferred Stock Series B

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.

Share on Social Networks: